Sneak Peek: Courtney Young on CRISPR Meets Duchenne: Scalable, Precise, Disruptive

What if gene editing could treat Duchenne Muscular Dystrophy at its genetic root—not just manage symptoms?Dr. Courtney Young, CEO of MyoGene Bio, is using CRISPR to address the underlying cause of Duchenne in a scalable, precise way that could transform rare disease treatment.🎙️ Full episode drops September 11In the complete interview, we dive into:• Why CRISPR is uniquely suited for Duchenne• Scalability, precision, and safety in gene editing• Navigating regulatory pathways• The future of gene therapy for rare diseasesSubscribe so you don't miss it.#SneakPeek #CRISPR #GeneEditing #RareDisease